IDH1 and oligodendroglioma: Vorasidenib, a dual IDH1/2 inhibitor, has demonstrated significant progression-free survival in the phase III INDIGO trial and, as of August 2024, holds FDA approval for patients aged 12 years and older with grade 2 astrocytoma or oligodendroglioma.